<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-023-44276-x
   </article-id>
   <article-id pub-id-type="manuscript">
    44276
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-023-44276-x
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/499
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699/255/2514
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/326/596/4130
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/326/596/2562
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /141
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Hatari ya kifo cha COVID-19 kwa watu wazima waliopokea chanjo za kuimarisha za COVID-19 nchini Uingereza
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" corresp="yes" id="Au1">
     <name name-style="western">
      <surname>
       Ward
      </surname>
      <given-names>
       Isobel L.
      </given-names>
     </name>
     <address>
      <email>
       Isobel.Ward@ons.gov.uk
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="corresp" rid="IDs4146702344276x_cor1">
      a
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au2">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-6848-5241
     </contrib-id>
     <name name-style="western">
      <surname>
       Robertson
      </surname>
      <given-names>
       Chris
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Agrawal
      </surname>
      <given-names>
       Utkarsh
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Patterson
      </surname>
      <given-names>
       Lynsey
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-1468-1823
     </contrib-id>
     <name name-style="western">
      <surname>
       Bradley
      </surname>
      <given-names>
       Declan T.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4101-4535
     </contrib-id>
     <name name-style="western">
      <surname>
       Shi
      </surname>
      <given-names>
       Ting
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-8553-2641
     </contrib-id>
     <name name-style="western">
      <surname>
       de Lusignan
      </surname>
      <given-names>
       Simon
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <name name-style="western">
      <surname>
       Hobbs
      </surname>
      <given-names>
       F. D. Richard
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-7022-3056
     </contrib-id>
     <name name-style="western">
      <surname>
       Sheikh
      </surname>
      <given-names>
       Aziz
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-0160-217X
     </contrib-id>
     <name name-style="western">
      <surname>
       Nafilyan
      </surname>
      <given-names>
       Vahé
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/021fhft25
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.426100.1
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2157 6840
      </institution-id>
      <institution content-type="org-name">
       Office for National Statistics
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Newport
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00n3w3b69
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.11984.35
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2113 8138
      </institution-id>
      <institution content-type="org-division">
       Department of Mathematics and Statistics
      </institution>
      <institution content-type="org-name">
       Strathclyde University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Glasgow
     </addr-line>
     <country country="GB">
      Scotland
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/023wh8b50
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.508718.3
      </institution-id>
      <institution content-type="org-name">
       Public Health Scotland
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Glasgow
     </addr-line>
     <country country="GB">
      Scotland
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/052gg0110
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.4991.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 8948
      </institution-id>
      <institution content-type="org-division">
       Nuffield Department of Primary Care Health Sciences
      </institution>
      <institution content-type="org-name">
       University of Oxford
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Oxford
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00hswnk62
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.4777.3
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0374 7521
      </institution-id>
      <institution content-type="org-division">
       Centre for Public Health
      </institution>
      <institution content-type="org-name">
       Queen’s University Belfast
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Belfast
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/03ek62e72
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.454053.3
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0494 5490
      </institution-id>
      <institution content-type="org-name">
       Public Health Agency
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Belfast
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/01nrxwf90
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.4305.2
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 7988
      </institution-id>
      <institution content-type="org-division">
       Usher Institute
      </institution>
      <institution content-type="org-name">
       University of Edinburgh
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Edinburgh
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution content-type="org-division">
       NIHR Applied Research Collaboration
      </institution>
      <institution content-type="org-name">
       Oxford Thames Valley
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Oxford
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <corresp id="IDs4146702344276x_cor1">
     <label>
      a
     </label>
     <email>
      Isobel.Ward@ons.gov.uk
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     16
    </day>
    <month>
     1
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="398">
    1
   </issue>
   <elocation-id>
    398
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      6
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="received">
     <day>
      20
     </day>
     <month>
      7
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      6
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="online">
     <day>
      16
     </day>
     <month>
      1
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © Crown 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     Crown
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Utangulizi
    </title>
    <p id="Par1">
     Kutokana na kuibuka kwa chanjo ya COVID-19 kumechangia katika kubadilisha mkondo wa janga la COVID-19. Ili kuhakikisha kuwa ulinzi unabaki juu kwa vikundi vilivyo hatarini, chanjo za kuimarisha nchini Uingereza zimekuwa zikitolewa kwa msingi wa umri na ulemavu wa kimatibabu. Tuliendesha tafiti ya kimataifa ya kumbukumbu kwa kutumia data ya sensa ya 2021 iliyounganishwa na rekodi za afya za kidijitali. Tuliweka miundo maalum ya Cox ili kuchunguza uhusiano kati ya hali za afya na hatari ya kifo cha COVID-19 na kifo cha sababu nyingine kwa watu wazima wenye umri wa miaka 50-100 nchini Uingereza waliochanjwa kwa chanjo ya kuimarisha mwaka 2022. Hapa tunapendekeza, kuwa na ulemavu wa kujifunza au Down Syndrome (uwiano wa hatari=5.07; 95% uwezo wa kujiamini=3.69-6.98), shinikizo la damu la mapafu au fibrosis (2.88; 2.43-3.40), ugonjwa wa motor neuron, sclerosis ya mgongo, myasthenia au ugonjwa wa Huntington (2.94, 1.82-4.74), saratani ya damu na tishu ya mifupa (3.11; 2.72-3.56), ugonjwa wa Parkinson (2.74; 2.34-3.20), saratani ya mapafu au mdomo (2.57; 2.04 hadi 3.24), ugonjwa wa kukosa kumbukumbu (2.64; 2.46 hadi 2.83) au ugonjwa wa cirrhosis ya ini (2.65; 1.95 hadi 3.59) ulihusishwa na hatari iliyoongezeka ya kifo cha COVID-19. Watu walio na saratani ya damu na tishu ya mifupa, ugonjwa wa figo sugu, ugonjwa wa fibrosis ya mapafu, shinikizo la damu la mapafu au fibrosis, au ugonjwa wa rheumatoid au lupus erythematosus walikuwa na hatari kubwa zaidi ya kifo cha COVID-19 ikilinganishwa na sababu zingine za kifo ikilinganishwa na watu ambao hawana magonjwa. Watunga sera wanapaswa kuendelea kutanguliza vikundi vilivyo hatarini kwa chanjo za kuimarisha za COVID-19 zinazofuata ili kupunguza hatari ya kifo cha COVID-19.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     Ward et al. utilise electronic health records to identify groups of adults (who had received a second booster dose of a COVID-19 vaccine) at elevated risk of COVID-19 death.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1117">
      Public Health and Health Services
     </kwd>
    </nested-kwd>
   </kwd-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      398
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2023
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      12
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      6
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2023_Article_44276.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Utanguzi
   </title>
   <p id="Par3">
    Maendeleo na kusambazwa kwa chanjo za COVID-19 kumechangia kupunguza kwa kiasi kikubwa maambukizi makali ya COVID-19, magonjwa, na vifo
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Hata hivyo, vikundi vingine vya wagonjwa vilibaki katika hatari kubwa ya kufa kwa COVID-19 licha ya kupokea mzunguko wa kwanza wa chanjo. Zaidi ya hayo, ufanisi umegunduliwa kupungua kwa wakati
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Kama matokeo, dosi za kuongeza kinga zilihitajika ili kuhakikisha kwamba idadi ya watu inabaki kulindwa dhidi ya matokeo makali, hasa kama vikwazo vinavyodhibiti maambukizi vimeondolewa. Katika Uingereza, dosi za kuongeza kinga za kwanza zilikuwa zinatolewa kwa kila mtu mzima baada ya miezi mitatu ya kupokea dozi ya pili ya chanjo ya COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
    </sup>
    . Dosi za kuongeza kinga zinazofuata zilitolewa kwa vikundi vilivyo katika hatari kubwa ya kulazwa hospitalini au kufa, kama vile watu wazima, watu wenye hali fulani za afya, au watu ambao walikuwa katika mazingira ya wagonjwa walio hatarini, kama vile wafanyakazi wa afya
    <sup>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
    </sup>
    .
   </p>
   <p id="Par4">
    Kuendelea kulinda watu walio hatarini zaidi dhidi ya COVID-19 kunabakia muhimu ili kupunguza athari za moja kwa moja na zisizo za moja kwa moja za SARS-CoV-2 kwenye afya ya idadi ya watu na huduma za afya, hasa kama nchi nyingi zinatanguliza usimamizi wa muda mrefu wa pandemiki ya COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    . Kutambua wagonjwa walio katika hatari kubwa zaidi ya matokeo makali kutokana na maambukizi ya SARS-CoV-2 ni muhimu ili kuhakikisha kwamba dosi za kuongeza kinga zinatolewa kwa wale wanaohitaji wakati wa kusimamia gharama ya programu ya chanjo. Ushahidi uliopo unapendekeza kwamba pamoja na umri, kuwa na magonjwa sambamba na hali maalum kama vile ugonjwa wa figo wa muda mrefu (CKD) unahusishwa na hatari kubwa ya kulazwa hospitalini na kufa kwa COVID-19 kwa watu waliopokea mpango kamili wa chanjo na dozi ya kwanza ya kuongeza kinga
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
    </sup>
    . Hata hivyo, hakuna ushahidi mkubwa kuhusu sababu za hatari za kufa kwa COVID-19 kwa watu waliopokea chanjo ya pili ya kuongeza kinga katika autumn 2022 nchini Uingereza. Kuelewa hatari kwa vikundi tofauti vya watu ni muhimu ili kuwafahamisha Kamati ya Pamoja ya Uchanji na Kingamwili (JCVI) nchini Uingereza na mabodi sawa ya kimataifa kufanya maamuzi kuhusu utangulizi wa chanjo za kuongeza kinga zinazofuata.
   </p>
   <p id="Par5">
    Katika tafiti hii, tulilenga kutambua vikundi vya watu wazima ambao walikuwa katika hatari kubwa ya kufa kwa COVID-19, kati ya wale waliopokea dozi ya pili ya chanjo ya COVID-19 kama sehemu ya kampeni ya kuongeza kinga ya Uingereza mwaka 2022. Kwa kutumia seti ya data iliyounganishwa kulingana na sensa ya 2021 iliyounganishwa na rekodi za huduma za afya za msingi na data ya usajili wa kifo, tulitathmini uwiano wa hatari ya kifo kinachohusisha COVID-19 kwa safu mbalimbali za tabia za kijamii na kiuchumi na sababu za hatari za kimatibabu. Pia tulitathmini uwiano wa hatari ya kifo ambacho hakijahusisha COVID-19, ili kuelewa ni vikundi gani vilikuwa katika hatari kubwa ya kufa kwa COVID-19 lakini vilikuwa na hatari ya chini ya kufa
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    .
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <p id="Par6">
    Kulikuwa na watu wazima 14,651,440 wenye umri kati ya miaka 50-100 katika idadi yetu ya watu waliopigiwa chapuo (maana = miaka 67.9, kiwango cha kawaida (SD) = 10.9); 46.9% walikuwa wa kiume na 90.4% walikuwa Waingereza weupe. Sifa za maelezo za idadi ya watu waliopigiwa chapuo yanatolewa katika Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM4">
     1
    </xref>
    <sup/>
    . Kati ya Septemba 1, 2022, na Aprili 11, 2023, kulikuwa na vifo 6,800 vya COVID-19 (52.2% wa kiume), na vifo 150,075 visivyo vya COVID-19, 1 (48.4% wa kiume). Umri wa wastani wa wale waliofariki kwa COVID-19 ulikuwa miaka 84.0 (SD = 8.87) na kwa vifo visivyo vya COVID-19 ulikuwa miaka 82.3 (SD = 9.85).
   </p>
   <p id="Par7">
    Umri ulikuwa mbashiri muhimu wa kifo cha COVID-19 na cha sio COVID-19; hatari ilikuwa mara 46 kubwa zaidi kwa mtu aliye na umri wa miaka 80 ikilinganishwa na mtu aliye na umri wa miaka 50 kwa kifo kinachohusiana na COVID-19 (HR:46.4;95%CI:43.0–50.0), na mara 30 kubwa zaidi kwa kifo cha sio COVID-19 (HR:29.6; 95%CI:29.2–30.0) (Fig.
    <xref ref-type="fig" rid="Fig1">
     1
    </xref>
    , Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ). Wanawake walikuwa na hatari ya chini ya kufa kwa COVID-19 (HR:0.63; 95%CI 0.6–0.66) na kifo cha sio COVID-19 (HR:0.76; 95%CI:0.75–0.77) ikilinganishwa na wanaume (Modeli 1) (Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ). Tulipata hatari kubwa ya chini ya kufa kwa COVID-19 kwa Waafrika wa Karibei (HR:0.46; 95%CI:0.29–0.73), Wahindi (HR:0.75;95%CI:0.58–0.95) na kundi jingine la kikabila (HR:0.62;95%CI:0.45–0.87) ikilinganishwa na kundi la Waingereza weupe kwa matokeo ya COVID-19 (Modeli 2) (Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ). Kuwa na uzito mkubwa sana au kupungua kwa uzito kunahusishwa na hatari kubwa ya COVID-19 (Kuwa na uzito mkubwa sana = HR:1.60;95%CI:1.35–1.89, Kupungua kwa uzito = HR:2.29;95%CI:2.04–2.59) na kifo cha sio COVID-19 (Kuwa na uzito mkubwa sana = HR:1.55;95%CI:1.50–1.60, Kupungua kwa uzito = HR:2.45;95%CI:2.39–2.51) (Modeli 3) (Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ). Kuripoti ulemavu ambao ulipunguza shughuli za kila siku za mtu kidogo au kwa wingi ulihusishwa na hatari kubwa ya COVID-19 na kifo cha sio COVID-19 ikilinganishwa na watu wasio na ulemavu (Modeli 4) (Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ).
    <fig/>
   </p>
   <p id="Par8">
    Kwa ujumla, hali zilizo na hatari kubwa zaidi ya kufa kwa COVID-19 ikilinganishwa na kutokuwa na hali hiyo (HR &gt; 2) zilikuwa watu walio na ulemavu wa kujifunza au Down’s syndrome (HR:5.07;95%CI:3.69–6.98), wale walio na shinikizo la damu la mapafu au uvimbe (HR:2.88;95%CI:2.43-3.40), ugonjwa wa neva za moto, sclerosis ya mgongoni, myasthenia au ugonjwa wa Huntington (HR:2.94;95%CI:1.82–4.74), saratani ya damu na tishu ya mifupa (HR:3.11;95%CI:2.72-3.56), ugonjwa wa Parkinson (HR:2.74;95%CI:2.34–3.20), saratani ya mapafu au midomo (HR:2.57:95%CI:2.04–3.24), ugonjwa wa kumbukumbu (HR:2.64;95%CI:2.46–2.83), au ugonjwa wa cirrhosis ya ini (HR:2.65;95%CI:1.95–3.59) (Fig.
    <xref ref-type="fig" rid="Fig2">
     2
    </xref>
    , Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ).
    <fig/>
   </p>
   <p id="Par9">
    Kwa kulinganisha HRs za vifo vya COVID-19 na vifo vya non-COVID-19, tulipata hatari kubwa zaidi ya vifo vya COVID-19 ikilinganishwa na vifo vya non-COVID-19 kwa hali zifuatazo: saratani ya damu au tishu ya mifupa, CKD, fibrosis ya mapafu, shinikizo la damu la mapafu au fibrosis au arthritis ya rheumatoid au lupus erythematosus ya kimfumo (SLE) (Jedwali la ziada
    <xref ref-type="supplementary-material" rid="MOESM1">
     2
    </xref>
    ). Kinyume chake, tulipata hatari ya kufa kutokana na sababu zingine za non-COVID-19 ilikuwa kubwa zaidi kuliko vifo vya COVID-19 kwa kuzingatia ugonjwa wa alzheimer na cirrhosis ya ini ikilinganishwa na wale ambao hawana magonjwa haya.
   </p>
   <p id="Par10">
    Katika muundo wa ziada ambao haujabadilishwa kwa ugonjwa mwingine wa comorbidities, hatari ya matokeo ya COVID-19 iliongezeka ikilinganishwa na muundo ambao hali zingine zilikuwa zimebadilishwa (Jedwali la ziada
    <xref ref-type="supplementary-material" rid="MOESM1">
     3
    </xref>
    ). Kwa bahati mbaya, kwa ajili ya asma katika muundo uliobadilishwa kwa hali zingine za afya (Muundo 5) HR kwa matokeo ya COVID-19 ilikuwa chini ya 1 (HR:0.84;95%CI:0.77-0.95), hata hivyo katika muundo wa ziada (uliojumuishwa kwa jinsia, umri, eneo, kikundi cha kikabila, na wakati wa kalenda) hatari ilikuwa kubwa zaidi kwa watu walio na asma ikilinganishwa na wale ambao hawana (HR:1.22;95%CI:1.11-1.33) (Jedwali la ziada
    <xref ref-type="supplementary-material" rid="MOESM1">
     3
    </xref>
    ).
   </p>
  </sec>
  <sec id="Sec3" sec-type="discussion">
   <title>
    Jadiliano
   </title>
   <p id="Par11">
    Uchunguzi huu wa kitaifa umegundua watu wazima ambao walibaki katika hatari kubwa ya kufa kutokana na COVID-19 baada ya kupokea chanjo ya kuimarisha ya pili nchini Uingereza mwaka 2022. Matokeo yetu yanaonyesha kwamba kuwa na ulemavu wa kujifunza au sindromu ya Down, shinikizo la damu la mapafu au fibrosis, ugonjwa wa motor neuron, sclerosis ya mgongo, myasthenia au ugonjwa wa Huntington, saratani ya damu au tishu ya mifupa, ugonjwa wa Parkinson, saratani ya mapafu au ya mdomo, ugonjwa wa alzheimer au cirrhosis ya ini zilikuwa zimeunganishwa kwa njia isiyo ya moja kwa moja na hatari kubwa zaidi ya kufa kutokana na COVID-19. Kwa saratani ya damu au tishu ya mifupa, CKD, fibrosis ya mapafu, shinikizo la damu la mapafu au fibrosis au arthritis ya rheumatoid au SLE ongezeko la hatari ilikuwa kubwa zaidi kwa vifo vya COVID-19 kuliko vifo vya non-COVID-19. Matokeo yetu yanaonyesha kwamba watu katika vikundi hivyo walikuwa katika hatari kubwa zaidi ya kufa kutokana na COVID-19 ikilinganishwa na sababu zingine za kifo. Kwa mfano, kwa watu walio na arthritis ya rheumatoid au SLE, hatari ya kufa kutokana na sababu zingine za non-COVID-19 haikuwa tofauti na watu bila magonjwa haya; hata hivyo, hatari ilikuwa kubwa zaidi kwa vifo vya COVID-19. Jambo muhimu, kikundi hiki halikuonekana kama moja ya magonjwa ya comorbidities yenye hatari kubwa zaidi ya vifo vya COVID-19, lakini uchambuzi wetu unaonyesha umuhimu wa hatari ya kufa kwa watu wanaoathiriwa zaidi na COVID-19 katika kikundi hiki ikilinganishwa na sababu zingine.
   </p>
   <p id="Par12">
    Kwa hali nyingi za afya, ongezeko la hatari ya kufa kutokana na COVID-19 lilikuwa sawa na, au chini ya, ongezeko la hatari ya kufa kutokana na sababu zingine za kifo, ikimaanisha kuwa ongezeko la hatari ya kufa kutokana na COVID-19 halikuwa tofauti na ongezeko la hatari ya kufa kutokana na sababu zingine. Wakati tunapata kwamba wagonjwa walio na asma walikuwa katika hatari kubwa ya kufa kutokana na COVID-19 baada ya kuzingatia umri, jinsia, kikundi cha kikabila, na eneo, tulipata kwamba kuwa na asma halikuwa na athari ya moja kwa moja kwa hatari ya kufa kutokana na COVID-19 baada ya kurekebisha kwa ugonjwa mwingine wa comorbidities, ikimaanisha kuwa asma haikuwa na athari ya moja kwa moja kwa hatari ya kufa kutokana na COVID-19.
   </p>
   <p id="Par13">
    Matokeo yetu yanathibitisha utafiti uliopita ambao ulichunguza matokeo ya vifo baada ya chanjo ya kuimarisha ya kwanza ya COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    . Kwa ujumla, nchini Uingereza, chanjo ya kuimarisha ya kwanza ya COVID-19 imeonekana kupunguza matokeo ya kutisha (kulazwa hospitalini na kifo), na vikundi maalum vikiwa katika hatari kubwa
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Watu wazima zaidi ya umri wa miaka 80, wale walio na magonjwa ya comorbidities na hali maalum kama vile CKD walipatikana kuwa katika hatari kubwa. Tafiti zilizofanywa nchini Marekani zilionyesha kwamba kwa wagonjwa walio na ugonjwa wa kinga ya mwili, walio na kisukari, walio na CKD au ugonjwa wa mapafu wa muda mrefu kulikuwa na ongezeko la hatari ya kuambukizwa na COVID-19 baada ya kupokea chanjo mbili za awali
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Ni muhimu kuzingatia matokeo yaliyotolewa katika utafiti wetu hayawezi kuonyesha tofauti za hatari ya kufa kutokana na COVID-19 baada ya kuambukizwa. Utafiti wetu unachunguza hatari ya kufa tangu wakati wa kupokea chanjo ya kuimarisha ya pili, sio tangu kuambukizwa. Ni dhahiri kwamba hatari ya kuambukizwa pia inatofautiana kwa sababu za kimatibabu, kwani wagonjwa walio katika hatari kubwa zaidi wanaweza kujilinda kwa kujitenga kijamii. Pia ni dhahiri kwamba wagonjwa walio katika hatari kubwa wanaweza kuwa katika hatari kubwa zaidi ya kuambukizwa kwa sababu ya kuishi katika maeneo ya pamoja au kuwa na mwingiliano wa mara kwa mara na wapangaji au wafanyakazi wa afya.
   </p>
   <p id="Par14">
    Kwa muhimu, kazi yetu inachunguza athari ya chanjo ya kuimarisha ya mwaka 2022 kwenye COVID-19, lakini pia matokeo ya non-COVID-19 kwa watu wazima nchini Uingereza. Matokeo yetu yanatoa ushahidi thabiti wa kuwafahamisha JCVI kuhusu vikundi gani vinapaswa kipaumbele kwa chanjo za ziada na uwezekano wa chanjo za ziada. Ni muhimu kuzingatia kwamba vikundi fulani ambavyo havina hatari kubwa zaidi ya kufa kutokana na COVID-19, vina hatari iliyoongezeka ikilinganishwa na sababu zingine za kifo na kwa hivyo vinapaswa kuwa kipaumbele muhimu.
   </p>
   <p id="Par15">
    Tafiti yetu ina nguvu kadhaa. Kwanza, tulitumia data ya kiwango cha idadi ya watu nchini Uingereza kulingana na uunganishaji wa kipekee wa sensa ya 2021 na rekodi za afya za kidijitali. Sifa za kijamii na kidemografia, ikijumuisha kundi la kabila, zilitolewa kutoka kwa sensa ya 2021, na zilikuwa sahihi na kuwa na upungufu mdogo, tofauti na baadhi ya rekodi za afya za kidijitali, ambapo kundi la kabila mara nyingi huwa halipatikani na si lazima liwe lililoripotiwa na mtu mwenyewe
    <sup>
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
    </sup>
    . Pili, tulibainisha mambo ya hatari ya kimatibabu kwa kutumia data ya huduma ya matibabu ya msingi. Tatu, tulitumia taarifa kuhusu sababu ya kifo ili kufafanua kifo cha COVID-19 na pia tulifanikiwa kuchunguza kifo cha si-COVID-19 kama kipimo cha kulinganisha na kutambua hali zipi zilizo na hatari kubwa zaidi ya kifo cha COVID-19 kuliko kifo cha si-COVID-19.
   </p>
   <p id="Par16">
    Kizuiaji muhimu cha tafiti yetu ni matumizi ya sensa ya 2021 kwa idadi yetu ya watu ina maana kwamba watu ambao hawakujibu sensa waliondolewa. Zaidi ya hayo, pia iliondoa wajibu wa sensa ambao hawakuweza kuunganishwa na Huduma ya Demografia ya Kibinafsi (PDS). Hata hivyo, data tulizotumia ilishughulikia 96.0% ya wale waliopokea chanjo ya kuimarisha nchini Uingereza mwaka wa 2022. Moja ya mapungufu ya kazi yetu ilikuwa ukosefu wa data kuhusu kuingia hospitalini kwa COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
    </sup>
    . Ili kudhibiti rasilimali kwa ufanisi na kuelewa ni vikundi gani viko katika hatari kubwa zaidi ya kuingia hospitalini, kazi zinazofuata zinazopata data za wakati zinapaswa kuzingatia kuingia hospitalini. Zaidi ya hayo, hatuwezi kuhesabu tabia ambazo zinaweza kugawanywa katika aina ya kulinda afya kama vile kupunguza mwingiliano wa kijamii katika tafiti hii. Kwa hiyo, ni muhimu kuzingatia kwamba kwa baadhi ya wagonjwa ambao hatari ya kuingia hospitalini au kifo ilikuwa muhimu zaidi baada ya maambukizi ya SARS-CoV-2, wanaweza kuendelea na kutengwa kijamii ili kuwalinda. Kwa hiyo, kwa vikundi vya watu ambapo hatari haikuwa ya juu kwa matokeo ya COVID-19, lakini kwa ujumla ilikuwa kubwa zaidi kwa kifo cha sababu zote tunapaswa kuendelea na kuweka kipaumbele kwa chanjo kwa watu hawa. Tafiti zinazofuata zinapaswa kuchunguza hali za kawaida (kwa mfano, kifua kikuu) ili kuelewa kama mwingiliano kati ya kuwa na uchunguzi wa kawaida pamoja na hali nyingine maalum husababisha utatizaji maalum wa matokeo mabaya ya COVID-19.
   </p>
   <p id="Par17">
    Kazi yetu inachunguza hatari ya kifo cha COVID-19 cha kipekee, pamoja na kifo cha si-COVID-19 katika kundi la watu wazima waliopokea chanjo ya kuimarisha mwaka wa 2022. Ili kudhibiti hatari ya COVID-19 kwa ufanisi, ni muhimu kwamba vikundi vilivyo hatarini zaidi vya watu vinawekwa kipaumbele kwa chanjo za kuimarisha za COVID-19. Tunasisitiza kwamba hatari ya kifo cha COVID-19, ikilinganishwa na kifo cha sababu nyingine zote, inabaki kuwa ya juu hasa kwa watu wazima walio na ulemavu wa kujifunza au down syndrome, shinikizo la damu la mapafu au fibrosis, ugonjwa wa neva za moto, sclerosis ya mgongo, myasthenia au ugonjwa wa Huntington, saratani ya damu na mifupa, ugonjwa wa Parkinson, saratani ya mapafu au ya mdomo, ugonjwa wa alzheimer, au ugonjwa wa cirrhosis ya ini. Vikundi hivi vya wagonjwa vinapaswa kuwa kipaumbele cha msingi kwa chanjo zinazofuata, matibabu, na tiba mpya. Zaidi ya hayo, tunasisitiza hatari inayohusiana na anuwai ya hali za afya na sifa za kijamii na kidemografia ambazo zinapaswa kufahamisha watunga sera na watafiti kwa demografia kuu ya maslahi kwa ajili ya utafiti na chanjo zinazofuata.
   </p>
  </sec>
  <sec id="Sec4" sec-type="methods">
   <title>
    Mbinu
   </title>
   <p id="Par18">
    Tafiti hii ilidhilliwa na Kamati ya Maadili ya Data ya Mstatisti wa Kitaifa (NSDEC) (Mamlaka ya Takwimu za Uingereza).
   </p>
   <sec id="Sec5">
    <title>
     Vyanzo vya data
    </title>
    <p id="Par19">
     Tulitumia data ya kiwango cha mtu binafsi inayojumuisha watu katika sensa ya 2021, iliyounganishwa na Huduma ya Demografia ya Kibinafsi (PDS), kupata nambari za NHS na kiwango cha uunganishaji cha 94.6%. Watu hawa walikuwa wameunganishwa kwa nambari ya NHS na Ofisi ya Takwimu za Kitaifa (ONS) kwa ajili ya usajili wa kifo (ikijumuisha kifo kilichosajiliwa hadi Aprili 26, 2023) na rekodi nyingine za afya za kidijitali. Rekodi za chanjo zilitolewa kutoka kwa Huduma ya Usimamizi wa Chanjo ya Kitaifa (NIMS)
     <sup>
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
     </sup>
     . Nchini Uingereza mwaka wa 2022, chanjo zote zilizotolewa kwa watu wazima (zaidi ya miaka 18) zilikuwa chanjo za mRNA zinazotolewa na watoa huduma za afya, vituo vya chanjo na maduka ya dawa. Vigezo vya afya vilivyotokana na rekodi za matibabu ya msingi vilipatikana kutoka kwa Huduma ya Uchimbaji wa Data ya Matibabu ya Msingi (GPES) kwa ajili ya Upangaji na Utafiti wa Pandemic version 4 (GDPPR) na kuunganishwa kwa nambari ya NHS. Seti ya data iliyounganishwa ilijumuisha data kuhusu watu 52 milioni wanaoishi nchini Uingereza, ambayo inashughulikia (kwa kuzingatia uunganishaji na wasiojibu) takriban 91.8% ya idadi ya watu nchini Uingereza siku ya sensa mwaka wa 2021.
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     Idadi ya watu wanaoshiriki katika utafiti
    </title>
    <p id="Par20">
     Tafiti hii ilikuwa tafiti ya kundi la watu waliopokea chanjo ya kuimarisha ya COVID-19 nchini Uingereza baada ya Septemba 1, 2022, waliohesabiwa katika sensa ya 2021, waliounganishwa na PDS, na walio na umri wa miaka 50-100 kwa wakati wa kupokea chanjo ya kuimarisha. Chanjo ya kuimarisha ya msimu wa autumn iliidhinishwa kama chanjo ya kuimarisha iliyotolewa baada ya Septemba 1, 2022, na angalau siku 84 tangu chanjo ya awali ya kimatibabu, na watu walipaswa kuwa na angalau chanjo mbili kabla ya chanjo ya kuimarisha (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ). Tazama jedwali la ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     kwa mtiririko wa sampuli.
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     Matokeo
    </title>
    <p id="Par21">
     Matokeo ya msingi ya utafiti huu ilikuwa kifo cha COVID-19, kilichofafanuliwa kama kifo chochote cha Kimataifa cha Uainishaji wa Magonjwa (ICD) na nambari za U07.1 na U07.2 zilizoandikwa popote kwenye cheti cha kifo, ambacho kilitokea hadi Aprili 11, 2023, na kiliandikwa hadi Aprili 26, 2023 (kikiruhusu siku 15 kwa ajili ya usajili wa kifo). Matokeo ya pili yalikuwa kifo cha non-COVID-19 cha sababu zote
     <sup>
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
     </sup>
     .
    </p>
    <p id="Par22">
     Watu walifuatiliwa kuanzia siku 14 baada ya tarehe ya chanjo ya kuimarisha ya autumn hadi Aprili 11, 2023. Muda wa hatari ulianza siku 14 baada ya chanjo ya kuimarisha na kumalizika kwenye wakati wa kifo (ama COVID-19 au nyingine), au mwisho wa utafiti (Aprili 11, 2023).
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     Maambukizi
    </title>
    <p id="Par23">
     Vigezo vilivyotumika katika muundo huu vilijumuisha sifa za kijamii na kiuchumi kutoka kwa Sensa ya 2021 na mambo ya hatari ya kimatibabu kutoka kwa data ya huduma za afya za msingi. Hali za kimatibabu zilitolewa kwa kutumia data za huduma za afya za msingi kutoka kwa Huduma ya Uchimbaji wa Data ya Utumishi wa Matibabu (GPES) kwa ajili ya Upangaji na Utafiti wa Janga la Pandemia, toleo la 4 (GDPPR) kulingana na ufafanuzi uliotumika na muundo wa utabiri wa hatari wa QCovid2, kwa kutumia data kati ya Machi 1, 2015, na Machi 21, 2021 (siku ya Sensa). Muundo wa utabiri wa hatari wa QCovid ulitumika na NHS nchini Uingereza ili kutambua watu ambao wana hatari kubwa ya kuugua COVID-19 na kifo. Muundo huu ulithibitishwa awali kwa kutumia data ya PHDA na Scotland
     <sup>
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
     </sup>
     . Vigezo vyote vilivyotumika katika muundo huu vimeorodheshwa katika Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      1
     </xref>
     <sup/>
     . Mambo yaliyokosekana kwa sifa za Sensa zilitambulishwa kwa kutumia mbinu ya kujaza mapungufu ya mshikamano wa karibu zaidi, ambayo ilitumika na ONS kwa kila kigezo cha Sensa ya 2011. Taarifa iliyokosekana kuhusu Indexi ya Uzito wa Mwili (BMI) ilitatuliwa kwa kujumuisha kundi la ‘Kukosekana’.
    </p>
   </sec>
   <sec id="Sec9">
    <title>
     Uchambuzi wa takwimu
    </title>
    <p id="Par24">
     Tulitumia regression ya Cox maalum ya sababu ili kuchunguza uhusiano kati ya kila moja ya hali za kuambukiza na hatari ya kifo cha COVID-19 na kifo cha sababu nyingine zote. Muda wa hatari ulianza siku 14 baada ya kupokea chanjo ya kuimarisha ya autumn na kumalizika ama kwenye wakati wa kifo au mwisho wa kipindi cha utafiti (Aprili 11, 2023). Kwa kila matokeo (COVID-19 na non-COVID-19), kwanza tulitumia muundo uliobadilishwa kwa umri (spline iliyozuiliwa na viambatanisho vya mpaka kwa asilimia 5 na 95 na viambatanisho 3 vya ndani), jinsia na wakati wa kalenda (spline iliyozuiliwa na viambatanisho vya mpaka kwa asilimia 5 na 95 na viambatanisho 3 vya ndani) (Muundo 1), kisha tukiongeza kikundi cha kabila na eneo (Muundo 2), BMI (Muundo 3) na ulemavu (Muundo 4)
     <sup/>
     .
    </p>
    <p id="Par25">
     Kwa kila moja ya hali za kuambukiza tulitumia muundo uliobadilishwa kwa hali zote za afya za QCovid, umri (spline), jinsia, wakati wa kalenda (spline), kikundi cha kabila na eneo (Muundo 5). Zaidi ya hayo, tulitumia miundo tofauti kwa kila hali ya afya, iliyoambatishwa kwa umri (spline iliyozuiliwa), jinsia, wakati wa kalenda (spline iliyozuiliwa), kikundi cha kabila na eneo. Kwa sababu za kompyuta, uchambuzi ulifanywa kwenye seti ya data inayojumuisha kila mtu aliyezifa na sampuli iliyozuiliwa ya 5% ya wale walioishi hadi mwisho wa utafiti. Ili kujaribu tofauti za hatari kati ya miundo ya COVID-19 na non-COVID-19 kwa watu walio na hali za kuambukiza, takwimu za Z zilitolewa kwa kila mgawo kutoka kwa miundo (Muundo 5) na data iliyobootstrapped (iteresheni 1000). Bootstrapping ilifanywa kwenye data iliyotumika, ikihakikisha uwiano wa matokeo (kifo na kuishi) ulihifadhiwa. Uchambuzi ulifanywa kwa kutumia Spark toleo 2.4.0 na R toleo 3.5.1. Hesabu zote zilizoonyeshwa zimepunguzwa hadi nambari 5 iliyo karibu zaidi, na thamani chini ya 10 zimezuiwa kwa sababu za kufichua.
    </p>
   </sec>
   <sec id="Sec10">
    <title>
     Ripoti ya muhtasari
    </title>
    <p id="Par26">
     Maelezo zaidi kuhusu muundo wa utafiti yanapatikana katika
     <xref ref-type="supplementary-material" rid="MOESM6">
      Fig. Nature Portfolio Reporting Summary
     </xref>
     iliyounganishwa na makala haya.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Shukrani
   </title>
   <p>
    Waandishi wanatamani kumshukuru Daniel Ayoubkhani kwa ujuzi wake wa takwimu na mwongozo wa mbinu. Kazi hii imefungwa na UKRI kama sehemu ya tuzo kwa Chuo Kikuu cha Birmingham kwa ajili ya Masomo ya Msingi ya COVID-19 (NCS), kwa “Mzunguko wa 1 wa COVID-19 Kinga – Masomo ya Msingi ya Taifa (Mzunguko wa 1 IMM-NCS)”. Nambari ya marejeleo ya tuzo ni MC_PC_20061.
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Michango ya waandishi
   </title>
   <p>
    I.W., V.N. na A.S. waliunda na kuunda tafiti. I.W. alipanga tafiti na kufanya uchambuzi wa takwimu, ambao ulithibitishwa na V.N., I.W., V.N., C.R., na A.S., walichangia katika kutafsiri matokeo. I.W. na V.N. waliandika rasimu ya awali. UA, LP, DB, TS, SdeL na RH walichangia katika ukaguzi na kuhariri makala na kuidhinisha makala ya mwisho.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Ukaguzi wa kielelezo
   </title>
   <sec id="FPar1">
    <title>
     Maelezo ya ukaguzi wa kielelezo
    </title>
    <p id="Par27">
     <italic>
      Nature Communications
     </italic>
     thanks the anonymous, reviewers for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa data
   </title>
   <p>
    The source data used in this study is subject to controlled access due to its sensitive nature. All statistical data used in this study are available from the Office for National Statistics website.
    <xref ref-type="sec" rid="Sec12">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa programu
   </title>
   <p>
    Code used in this study is available on Github [link]
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Mashindano ya maslahi
    </title>
    <p id="Par28">
     SdeL has received University funding for vaccine related research from AstraZeneca, GSK, Moderna, Pfizer, Sanofi, Seqirus, and Takeda, and been advisory board members for AstraZeneca, GSK, Sanofi and Seqirus. The remaining authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Marudio
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kerr
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
      </article-title>
      <source>
       Int. J. Epidemiol.
      </source>
      <year>
       2023
      </year>
      <volume>
       52
      </volume>
      <fpage>
       22
      </fpage>
      <lpage>
       31
      </lpage>
      <pub-id pub-id-type="doi">
       10.1093/ije/dyac199
      </pub-id>
      <pub-id pub-id-type="pmid">
       36272418
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Agrawal
        </surname>
        <given-names>
         U
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
      </article-title>
      <source>
       Lancet
      </source>
      <year>
       2022
      </year>
      <volume>
       400
      </volume>
      <fpage>
       1305
      </fpage>
      <lpage>
       1320
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/S0140-6736(22)01656-7
      </pub-id>
      <pub-id pub-id-type="pmid">
       36244382
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9560746
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="other">
      Rough E., Coronavirus: Covid-19 booster vaccines frequently asked questions, 2022. [Online]. Available:
      <ext-link ext-link-type="uri" xlink:href="https://commonslibrary.parliament.uk/research-briefings/cbp-9332/">
       https://commonslibrary.parliament.uk/research-briefings/cbp-9332/
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="other">
      <italic>
       Greenbook Chapter:
      </italic>
      COVID-19 -
      <italic>
       SARS-CoV-2
      </italic>
      , no. April. 2023. [Online]. Available:
      <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1153300/Greenbook-chapter-14a-26April2023.pdf">
       https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1153300/Greenbook-chapter-14a-26April2023.pdf
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="other">
      World Health Organization, Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic, May 2023. Avilable:
      <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic">
       https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Agrawal
        </surname>
        <given-names>
         U
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study,
      </article-title>
      <source>
       Lancet Respir. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       9
      </volume>
      <fpage>
       1439
      </fpage>
      <lpage>
       1449
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXitFOlsLvJ
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/S2213-2600(21)00380-5
      </pub-id>
      <pub-id pub-id-type="pmid">
       34599903
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8480963
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics, Census 2021. Available:
      <ext-link ext-link-type="uri" xlink:href="https://census.gov.uk/">
       https://census.gov.uk/
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nafilyan
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <name>
        <surname>
         Ward
        </surname>
        <given-names>
         IL
        </given-names>
       </name>
       <name>
        <surname>
         Robertson
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Sheikh
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Evaluation of risk factors for postbooster Omicron COVID-19 deaths in England
      </article-title>
      <source>
       JAMA Netw. Open
      </source>
      <year>
       2022
      </year>
      <volume>
       5
      </volume>
      <fpage>
       E2233446
      </fpage>
      <pub-id pub-id-type="doi">
       10.1001/jamanetworkopen.2022.33446
      </pub-id>
      <pub-id pub-id-type="pmid">
       36074469
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9459656
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Smits
        </surname>
        <given-names>
         PD
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities
      </article-title>
      <source>
       Vaccine
      </source>
      <year>
       2023
      </year>
      <volume>
       41
      </volume>
      <fpage>
       2447
      </fpage>
      <lpage>
       2455
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/j.vaccine.2023.02.038
      </pub-id>
      <pub-id pub-id-type="pmid">
       36803895
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9933320
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics, Understanding consistency of ethnicity data recorded in health-related administrative datasets in England: 2011 to 2021, 2023.
      <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/releases/understandingconsistencyofethnicitydatarecordedinhealthrelatedadministrativedatasetsinengland2011to2021">
       https://www.ons.gov.uk/releases/understandingconsistencyofethnicitydatarecordedinhealthrelatedadministrativedatasetsinengland2011to2021
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Berec
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia
      </article-title>
      <source>
       PLoS One
      </source>
      <year>
       2022
      </year>
      <volume>
       17
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       13
      </lpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0270801
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="other">
      NHS, Personal Demographics Service. Available:
      <ext-link ext-link-type="uri" xlink:href="https://digital.nhs.uk/services/demographics">
       https://digital.nhs.uk/services/demographics
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics, Mortality statistics in England and Wales QMI, 2022. Available:
      <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/mortalitystatisticsinenglandandwalesqmi">
       https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/mortalitystatisticsinenglandandwalesqmi
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="other">
      NHS England, The National Immunisation Management Service. Available:
      <ext-link ext-link-type="uri" xlink:href="https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/#immunisation">
       https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/#immunisation
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="other">
      World Health Organization, ICD-10 Version:2019. Available:
      <ext-link ext-link-type="uri" xlink:href="https://icd.who.int/browse10/2019/en#/U07.1">
       https://icd.who.int/browse10/2019/en#/U07.1
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="other">
      QCovid® risk calculator. Available:
      <ext-link ext-link-type="uri" xlink:href="https://www.qcovid.org/">
       https://www.qcovid.org/
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nafilyan
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in England
      </article-title>
      <source>
       Lancet Digit. Heal.
      </source>
      <year>
       2021
      </year>
      <volume>
       3
      </volume>
      <fpage>
       e425
      </fpage>
      <lpage>
       e433
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXis1SmsbY%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/S2589-7500(21)00080-7
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="other">
      Simpson C. R. et al. External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland,
      <italic>
       Thorax
      </italic>
      , p. thoraxjnl-2021-217580, 2021,
      <ext-link ext-link-type="doi" xlink:href="10.1136/thoraxjnl-2021-217580">
       https://doi.org/10.1136/thoraxjnl-2021-217580
      </ext-link>
      .
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec11">
     <title>
      Taarifa za ziada
     </title>
     <p id="Par29">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM4_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Data 1
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM5_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Data 2
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM6_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec12">
     <title>
      Data ya chanzo
     </title>
     <p id="Par30">
      <supplementary-material content-type="local-data" id="MOESM7" xlink:title="Source data">
       <media mime-subtype="plain" mimetype="text" xlink:href="MediaObjects/41467_2023_44276_MOESM7_ESM.csv">
        <caption xml:lang="en">
         <p>
          Source Data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    Taarifa za ziada
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-023-44276-x">
     https://doi.org/10.1038/s41467-023-44276-x
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
